

**REMARKS**

Entry of the foregoing, reexamination and reconsideration of the above-identified application are respectfully requested.

In the Official Action, the Examiner rejected Claims 30 and 31 under 35 U.S.C. 112, second paragraph, as being allegedly indefinite. For the purpose of expediting prosecution only, Claim 30 has been clarified by amending as suggested by the Examiner. In light of the amendment, withdrawal of this rejection is respectfully requested.

The Examiner also rejected Claims 39-41 under 35 U.S.C. 112, first paragraph, as allegedly not being enabled by the specification, based only the ability of the primer pairs of Claim 41 to amplify both Lelystad and Iowa strain viruses. This rejection follows the undersigned's discussion with the Examiner, wherein the undersigned related recently obtained clarification of the results presented in the specification at pp. 88-89. This section of the specification had previously been, without intent, misconstrued. As such, the undersigned had contacted the Examiner to indicate that Applicants intended to expressly cancel Claim 41 and withdraw the previous argument that those primers would be effective in the method of Claim 39. Applicants again thank the Examiner for her discussion of this issue in the Official Action. As such, by the present amendment, Claim 41 has been cancelled.

Applicants thank the Examiner for acknowledging that Claims 39-40 would be otherwise enabled by the specification. However, in light of the Examiner's rejection of these claims pursuant to 35 U.S.C. 103(a), and for the purpose of expediting prosecution only, Claims 39-40 have been cancelled from this application, without disclaimer or prejudice to their being pursued in a divisional or continuation application. As such, the rejection under 35 U.S.C. 103(a) is rendered moot.

It is respectfully submitted that all rejections have been overcome by the above amendments. Thus, a Notice of Allowance is respectfully requested.

In the event that there are any questions relating to this Amendment or to the application in general, it would be appreciated if the Examiner would contact the undersigned attorney by telephone at (202) 778-6150 so that prosecution of the application may be expedited.

Respectfully submitted,  
BINGHAM MCCUTCHEN, LLP

Date: July 13, 2005

By: Sharon E. Crane  
Sharon E. Crane, Ph.D.  
Registration No. 36,113

Bingham McCutchen LLP  
Three Embarcadero Center  
San Francisco, California 94111-4067  
Local Telephone: (202) 778-6150  
Local Facsimile: (202) 778-6155